[{"address1": "245 Main Street", "address2": "Second Floor", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 500 8080", "website": "https://immuneering.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.", "fullTimeEmployees": 65, "auditRisk": 6, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 1.41, "open": 1.38, "dayLow": 1.38, "dayHigh": 1.455, "regularMarketPreviousClose": 1.41, "regularMarketOpen": 1.38, "regularMarketDayLow": 1.38, "regularMarketDayHigh": 1.455, "beta": -0.596, "forwardPE": -0.75263155, "volume": 147798, "regularMarketVolume": 147798, "averageVolume": 386116, "averageVolume10days": 284820, "averageDailyVolume10Day": 284820, "bid": 1.42, "ask": 1.45, "bidSize": 500, "askSize": 600, "marketCap": 42404360, "fiftyTwoWeekLow": 1.3, "fiftyTwoWeekHigh": 11.06, "fiftyDayAverage": 1.561, "twoHundredDayAverage": 4.9987, "currency": "USD", "enterpriseValue": -24492794, "floatShares": 17410374, "sharesOutstanding": 29653400, "sharesShort": 3527138, "sharesShortPriorMonth": 2730363, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.1189, "heldPercentInsiders": 0.29152, "heldPercentInstitutions": 0.34876, "shortRatio": 9.2, "shortPercentOfFloat": 0.1598, "impliedSharesOutstanding": 29653400, "bookValue": 2.655, "priceToBook": 0.5386064, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -54175280, "trailingEps": -1.86, "forwardEps": -1.9, "enterpriseToEbitda": 0.417, "52WeekChange": -0.8489968, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "IMRX", "underlyingSymbol": "IMRX", "shortName": "Immuneering Corporation", "longName": "Immuneering Corporation", "firstTradeDateEpochUtc": 1627651800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e5829551-96d1-35fc-9c6d-d258079bf8f6", "messageBoardId": "finmb_308350677", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.43, "targetHighPrice": 25.0, "targetLowPrice": 1.5, "targetMeanPrice": 11.64, "targetMedianPrice": 12.0, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 71278352, "totalCashPerShare": 2.404, "ebitda": -58693296, "totalDebt": 4381256, "quickRatio": 13.767, "currentRatio": 14.379, "debtToEquity": 5.565, "returnOnAssets": -0.37727, "returnOnEquity": -0.61384, "freeCashflow": -31724910, "operatingCashflow": -50041728, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]